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Background and aims: The purpose of this study was to investigate the effect of eight weeks of resistance training (RT) using elastic bands 
together with green coffee supplement on novel hepatic steatosis biomarkers (hepatic steatosis index [HSI] and Framingham steatosis index 
[FSI]) in middle-aged obese women. 
Materials and Methods: This study was a double-blind randomized clinical trial performed on the basis of the CONSORT Statement at 
Shahrekord University in Iran (summer 2018). For this purpose, 60 obese women aged 30-60 years with a body mass index (BMI) of >30 kg/
m2 were selected to participate in this study and then they were randomly assigned to one of the following four groups: green coffee (GC, 
n=15), resistance training and placebo (RT+P, n=15), green coffee and resistance training (GC+RT, n=15), and placebo groups (P, n=15). 
Results: The results showed no significant differences in FSI (P=0.822) and HSI (P=0.752) between four groups. However, there were 
significant increases in high density lipoprotein (HDL) in the RT+P (P=0.050) and GC+RT groups (P=0.032) and significant decreases in 
total cholesterol (TC)  in the RT+P (P=0.023), GC+RT (P=0.006), and GC groups (P=0.041). 
Conclusion: The reduction of hepatic steatosis biomarkers in these individuals may require a longer period of resistance workouts or other 
exercises.
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Introduction 
Due to lifestyle changes such as dietary habits and 
insufficient physical activities, the obesity rate is growing 
(500 million people are clinically obese) worldwide, 
especially in Iran (1). It has been reported that 50% of 
obese women suffer from nonalcoholic fatty liver disease 
(NAFLD) (2). Many researchers have also made efforts to 
identify and introduce a large number of novel biomarkers 
for predicting hepatic steatosis and monitoring responses 
to therapeutic strategies. Hepatic steatosis index (HSI) 
and Framingham steatosis index (FSI) are considered as 
useful tools, which have been developed in recent years 
for primary prevention of hepatic disease at individual and 
clinical levels (3-5). 
The major intervention offered for fatty liver in obese 
people is lifestyle changes including weight loss, medicinal 
foods, as well as regular exercise (6). Typically, poor 
adherence to aerobic exercises may be problematic in 
obese women due to a need for high aerobic capacity and 
early exhaustion (7). Therefore, scarce data have recently 
shown that the use of resistance exercise (RT) modality has 
become more popular in obese adults to improve hepatic 
disorders (8,9). The liver-related benefits of RT for obese 
women include reduction of visceral adipose tissue and 
obesity indices (10). Additionally, lower cardiorespiratory 
demand is required by resistance exercises that are 
associated with similar metabolic benefits (9,11). 
Several studies have reported that the consumption of 
green coffee (GC), as a rich source of bioactive chlorogenic 
acid (CGA), plays a protective role against the development 
of hepatic risk factors (12,13), obesity (14), and increased 
hepatic triglyceride (TG) levels (15). Recently, exercise 
scientists have suggested the complementary role of exercise 
and herbal medicine (16,17). It has also been reported that 
physical training may accelerate certain adaptations when 
it is combined with herbal medicines that may not be 
achieved in response to pharmaceuticals alone (18,19). To 
the best of our knowledge, there has yet been no published 
study on the impact of GC consumption and elastic RT 
program on novel noninvasive indices for hepatic steatosis 
in obese women. Therefore, the purpose of this study was 
to compare the effects of GC consumption and elastic 
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RT program on novel noninvasive biomarkers for hepatic 
steatosis (HSI and FSI) in obese women.
Materials and Methods 
This study was a double-blind randomized clinical trial 
performed on the basis of the CONSORT Statement 
at Shahrekord University, Iran (20). The protocol was 
registered in the Iranian Registry of Clinical Trials 
(identifier: IRCT2017090419995N9). Information about 
the study design, objectives, procedures, as well as benefits 
and potential risks were presented at the beginning of the 
study and then the informed consent was obtained from 
each participant. The flow diagram of the study design was 
presented in Figure 1. 
Participants were recruited through brochures and 
newspaper announcements (Shahrekord, Iran) according 
to the following criteria. The participants were sedentary, 
30-60 years old, non-menopause, and class I/II obese 
(39.9<BMI>30 kg/m2). Sedentary was defined as no 
more than 20-minute exercise per week over the past 6 
months. The exclusion criteria were as follows: having 
thyroid disorder, being nursing mothers, following regular 
exercise training and diet, using weight loss drugs or 
phytochemicals, having blood pressure ≥160/100 mm 
Hg, fasting triglyceride ≥500 mg/dL, having a history of 
cardiovascular diseases, cancer, hepatic diseases, metabolic 
syndromes, and hormonal disorders, using hormone 
therapy, alcohol abuse, using steatogenic drugs, as well 
as being pregnant, using supplements on a regular basis 
or participating in other clinical trials over the past 3 
months (3). The sample size was calculated considering: 
(a) two-way ANOVA, (b) 4 groups, (c) type I error=5%, 
(d) type II error= 20%, (e) power of statistical test=80%, 
and (f ) effect size=0.20. The sample size in this study was 
measured using G*Power 3 (21). The effect size of GC 
was also estimated to be 5 IU/L for serum ALT levels (3). 
Using a statistical power of 0.80, an effect size of 1.08, and 
an alpha value of 0.05, a total sample size of 80 individuals 
(20 per group) was determined considering the potential 
dropouts of 15%. 
The patients were randomized by block allocation with a 
block size of 6 by a research assistant who was not involved 
in this research using a computer-generated random 
number sequence. Participants were stratified according 
to two cut-offs for stratifications of age (30-50 or 51-60 
years), BMI (25-35 or 36-48 kg/m2), and HbA1c (6.5-
8.5% or ≥8.6%).  
After baseline assessments, a total of 60 eligible subjects 
(39.9 <BMI> 30 kg/m2) were randomized by block 
allocation with a block size of 8 by a research assistant 
who was not involved in this research to one of the four 
groups [(resistance training and placebo group (RT+P, 
n=15), green coffee supplement (GC, n=15), green coffee 
supplement and resistance training (GC+RT, n=15), 
Figure 1. CONSORT flow diagram .
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and placebo group (P, n=15)] in a ratio of 1:1:1:1 using 
a computer-generated random number sequence. The 
allocation sequence was concealed in sealed opaque 
envelopes, which were not opened until the baseline 
assessment was completed. The participants were also 
blind to group allocation and underwent an 8-week 
intervention. Two subjects from RT+P group, two subjects 
from the P group, one subject from GC+RT group, and 
one subject from the GC group withdrew from the trial 
following randomization. Moreover, dropout rates were 
calculated as the percentage of the participants failed to 
continue their participation for 8 weeks. 
Commercially prepared GC bean capsules were used 
in this study. Additional information is represented in 
supplementary data. Details of the exercise training 
program are illustrated in the supplementary file. Briefly, 
RT was done using Thera-band products (Hygenic Co., 
Akron, OH). The colors of the band include yellow, red, 
green, and blue. During the 8 weeks of resistance training, 
all subjects had three sessions per week and were monitored 
by a licensed senior exercise physiologist who was blind 
to the study group members. Additional information is 
represented in supplementary data file and supplementary 
Tables 1 and 2.
Calculation of Novel Hepatic Steatosis Indices 
HSI = 8 (ALT/AST) ratio+BMI+2 (4,22).
FSI = -7.981+0.011×age (years)-0.173×BMI (kg/m2) + 
0.007 x triglycerides (mg/dL)+1.1×ALT/AST ratio ≥1.33 
(yes=1, no=0) (23).
To compare the pretest and posttest scores in each 
group, a dependent t test was used and all the values were 
presented as mean ± standard deviation. Kolmogorov-
Smirnov test was also performed for testing normality 
of distribution. One-way ANOVA was used for baseline 
comparisons between four groups. Two-way ANOVA 
(Group * Time) was conducted to compare the changes in 
experimental and control groups after eight weeks. When 
a significant F-value was achieved, the Bonferroni post hoc 
test was used to investigate the differences between the 
groups. Significance level (P) was considered to be <0.05. 
Results
The participants’ baseline characteristics were shown in 
Table 1. None of the subjects experienced an adverse event 
as a result of participation in this research which might 
need medical treatment or any clinical findings required 
for medical referral. Participants of the present study had 
satisfactory adherence to the interventions. The dropout 
Table 1. Descriptive characteristics of P+R, GC+R, GC, and P groups at baseline level









Age (y) 37.46±6.70 35.15±5.29 39.85±6.23 39.67±5.59 0.171
Height (cm) 157.77±6.26 158.79±7.06 159±5.34 161.15±4.07 0.511
Body mass (kg) 82.55±12.72 86±10.08 86.03±8.46 85.72±7.26 0.113
WC (cm) 99.69±7.80 100.54±7.58 104±6.76 102.42±7.07 0.424
BMI (kg/m2) 33.12±2.52 34.1±3.31 34.07±3.43 33.01±2.59 0.092
Body fat (%) 45.59±2.97 46.16±2.37 44.43±3.64 43.93±2.66 0.052
WHR 0.979±0.12 0.96±0.05 0.89±0.05 0.88±0.06 0.064
Daily calorie (kcal/d) 1816.5±92.02 1868.4±74.77 1890.4±108.9 1902.7±1103.9 0.642
Carbohydrate % 53.92±4.39 57.92±5.76 56.5±7.79 55.53±4.43 0.391
Fat % 29.92±5.02 28.14±5.47 31.76±7.53 29.38±4.72 0.708
Protein % 16.15±5 13.93±4.25 11.46±4.49 15.08±5.31 0.396
HDL (mg/dL) 48.27±4 48.44±6.95 42.91±4.76 47.17±7.96 0.072
LDL (mg/dL) 101.37±24.83 87.86±17.74 91.17±23.15 99.47±28.79 0.401
TG (mg/dL) 159.46±43.59 161.5±35.34 147.36±53.58 151.54±38.6 0.809
TC (mg/dL) 188.61±35.33 172±27.39 166.64±26.71 183.38±26.41 0.196
ALT (IU/L) 15.31±2.81 15.36±1.55 17.14±2.48 14.63±1.99 0.034*
AST (IU/L) 15.61±3.99 16.29±4.23 16.64±4.63 15.58±3.87 0.890
GGT (IU/L) 14.75±5.5 14.29±6.23 14.49±4.19 16.51±4.12 0.667
FBG (mg/dL) 94.61±8.12 94.36±10.67 94.07±7.39 91.46±10.28 0.477
Insulin (IU/L) 15.69±2.51 16.74±1.93 16.35±3.08 15.17±3.02 0.163
FSI -0.78±0.76 -0.48±0.79 -0.52±0.87 -0.90±0.49 0.401
HSI 73.69±7.25 76.42±6.21 76.45±6.52 74.11±6.91 0.700
Abbreviations: RT, Resistance training; GC, Green coffee; P, Placebo; ALT, Alanine aminotransferases; AST, Aspartate aminotransferases; GGT, Gamma glutamyl 
transferase; HSI, Hepatic steatosis index; FSI, Framingham steatosis index; FBG, Fasting blood glucose; BMI, Body mass index; HDL, High density lipoprotein; TG, 
Triglyceride; WC, Waist circumference; MAP, Mean arterial pressure; WHR, Waist-to-hip ratio; TC, Total cholesterol.
One-way ANOVA was used for baseline comparisons in four groups. * significant differences between groups at baseline level.
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rate was only 10%, which was less than conservative 
anticipation in this study. No significant differences were 
observed in dropout rates between the four groups.
Table 2 shows the body composition of the participants 
in the experimental groups. In RT+P group, there were 
significant decreases in body mass (P=0.001), waist 
circumference (WC) (P=0.001), BMI (P=0.001), 
body fat percentage (P=0.001), waist-to-hip ratio 
(WHR) (P=0.015), and mean daily calorie (P=0.032). 
Additionally, in GC+RT group, there were significant 
decreases in body mass (P=0.001), WC (P=0.001), BMI 
(P=0.001), body fat percentage (P=0.001), mean daily 
calorie (P=0.002), carbohydrate (P=0.006), and protein 
(P=0.001). A significant decrease in body mass (P=0.002), 
WC (P=0.001), BMI (P=0.003), and body fat percentage 
(P=0.001) was observed in the GC group. The placebo 
group also showed no changes in all the body composition 
variables (P≥0.05). There were no significant differences 
between the four groups in all body composition and diet 
characteristics variables (P≥0.05).
In the RT+P group, high density lipoprotein (HDL) 
(P=0.007), TG (P=0.012), GGT (P=0.050), glucose 
(P=0.001), FSI (P=0.034), and HSI (P=0.014) significantly 
decreased. In the GC+RT group, there was a significant 
decrease in HDL (P=0.010), TG (P=0.003), aspartate 
aminotransferases (AST) (P=0.007), glucose (P=0.001), 
FSI (P=0.021), and HSI (P=0.027). Moreover, in the GC 
group, HSI (P=0.023) significantly declined. There were 
no significant differences in the P group (P≥0.05) (Table 
3).
Furthermore, the results of two-way ANOVA showed 
no significant differences in novel hepatic steatosis indices 
(FSI, and HSI) between the four groups (P≥0.05). 
However, there were significant differences in HDL 
(P=0.020) and total cholesterol (TC) (P=0.045). After 
post-hoc comparisons, it was found that HDL in the RT+P 













Pre-test 82.55±12.72 86±10.08 86.03±8.46 85.72±7.26
0.730Post-test 79.73±11.78 83.09±10.44 82.47±9.01 84.18±6.49
P value (within groups) 0.001 0.001 0.002 0.141
WC (cm)
Pre-test 99.69±7.80 100.54±7.58 104±6.76 102.42±7.07
0.385Post-test 97.12±7.11 98±7.47 100.88±6.06 101.37±7.26
P value (within groups) 0.001 0.001 0.001 0.314
BMI (kg/m2)
Pre-test 33.12±2.52 34.1±3.31 34.07±3.43 33.01±2.59
0.892Post-test 32±4.30 32.91±3.01 32.66±3.57 32.51±3.46
P value (within groups) 0.001 0.001 0.003 0.088
Body fat (%)
Pre-test 45.59±2.97 46.16±2.37 44.43±3.64 43.93±2.66
0.398Post-test 43.27±3.24 43.93±2.22 42.37±3.58 43.20±2.13
P value (within groups) 0.001 0.001 0.001 0.129
WHR
Pre-test 0.979±0.12 0.96±0.05 0.89±0.05 0.881±0.06
0.054Post-test 0.926±0.09 0.948±0.05 0.888±0.12 0.88±0.06
P value (within groups) 0.015 0.192 0.786 0.791
Daily calorie (kcal/d)
Pre-test 1816.5±92.02 1868.4±74.77 1890.4±108.9 1902.7±103.9
0.117Post-test 1629.5±54.51 1699.1±66.50 1702.2±85.16 1949±90.92
P value (within groups) 0.032 0.002 0.119 0.470
Carbohydrate %
Pre-test 53.92±4.39 57.92±5.76 56.5±7.79 55.53±4.43
0.808Post-test 53.84±6.72 49.64±7.57 52.36±10.03 58.38±5.78
P value (within groups) 0.966 0.006 0.255 0.085
Fat %
Pre-test 29.92±5.02 28.14±5.47 31.76±7.53 29.38±4.72
0.643Post-test 27±5.43 30.09±4.49 32.57±9.12 27.31±4.64
P value (within groups) 0.153 0.293 0.756 0.294
Protein %
Pre-test 16.15±5 13.93±4.25 11.46±4.49 15.08±5.31
0.532Post-test 19.92±4.54 20.36±5.81 15.38±4.01 14.23±4.25
P value (within groups) 0.095 0.001 0.064 0.702
Abbreviations: RT, Resistance training, GC, Green coffee; P, placebo; BMI, Body mass index; HDL, High density lipoprotein; TG, Triglyceride; WC, Waist 
circumference; MAP, Mean arterial pressure; WHR, Waist-to-hip ratio; 
A paired sample t test was used to conduct intra-group comparisons (pre-post changes). A two-way ANOVA test was also used to investigate differences between 
groups. Bonferroni correction was also applied as post-hoc test.
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(P=0.050) and GC+RT groups (P=0.032) significantly 
increased, and TC groups significantly decreased in the 
RT+P (P=0.023), GC+RT (P=0.006), and GC (P=0.041) 
(Table 3).
Discussion
As obesity and fatty liver disease have similar 
pathophysiologic mechanisms such as inflammation, 
insulin resistance, and oxidative stress, it has been 
hypothesized that obesity is associated with increased 
risk of NAFLD (24). In this respect, a study found that 
more than 91% of obese individuals (BMI >30 kg/m2) 
showed evidence of fatty liver (25). However, there have 
yet been no studies comparing the effect of RT with elastic 
bands and consuming GC supplement on some novel 
noninvasive hepatic disorder indices in obese middle-aged 
women. 
The present clinical trial was carried out to examine 
the effects of 500 mg/d of GC supplementation along 
with resistance elastic band training during eight weeks 
in women with obesity. Significant reductions were also 
observed in serum HDL level in RT+P and GC+RT groups 
compared with the P group. Moreover, GC+RT had no 
significant impacts on serum LDL, TG, ALT, AST, GGT, 













Pre-test 48.27±4 48.44±6.95 42.91±4.76 47.17±7.96
0.020*Post-test 51.06±3.92 51.41±7.27 43.91±5.81 47.40±7.92
P value (within groups) 0.007 0.010 0.356 0.885
LDL (mg/dL)
Pre-test 101.37±24.83 87.86±17.74 91.17±23.15 99.47±28.79
0.206Post-test 88.63±31.16 78.06±22.29 85.29±21.38 103.05±28.93
P value (within groups) 0.026 0.074 0.182 0.540
TG (mg/dL)
Pre-test 159.46±43.59 161.5±35.34 147.36±53.58 151.54±38.6
0.908Post-test 50.46±40.35 148.29±34.45 142.23±51.71 150.77±39.81
P value (within groups) 0.012 0.003 0.071 0.942
TC  (mg/dL)
Pre-test 188.61±35.33 172±27.39 166.64±26.71 183.38±26.41
0.045*Post-test 180.06±35.02 160.01±24.08 161.29±25.06 192.22±18.39
P value (within groups) 0.088 0.015 0.243 0.020
ALT (IU/L)
Pre-test 15.31±2.81 15.36±1.55 17.14±2.48 14.63±1.99
0.061Post-test 14.23±3 14.50±2.77 16.57±3.11 14.95±2.10
P value (within groups) 0.073 0.152 0.241 0.559
AST (IU/L)
Pre-test 15.61±3.99 16.29±4.23 16.64±4.63 15.58±3.87
0.704Post-test 14.54±2.99 14±3.46 16.36±2.82 15.77±4.02
P value (within groups) 0.084 0.007 0.725 0.806
GGT (IU/L)
Pre-test 14.75±5.5 14.29±6.23 14.49±4.19 16.51±4.12
0.184Post-test 12.3±5.21 14.1±4.82 14.23±3.22 17.35±4.93
P value (within groups) 0.050 0.878 0.852 0.608
FBG (mg/dL)
Pre-test 94.61±8.12 94.36±10.67 94.07±7.39 91.46±10.28
0.058Post-test 89.08±9.70 84.5±11.02 91.79±8.50 99.92±20.12
P value (within groups) 0.001 0.001 0.071 0.053
Insulin (IU/L)
Pre-test 15.69±2.51 16.74±1.93 16.35±3.08 15.17±3.02
0.166Post-test 14.62±2.64 15.39±2.12 15.63±2.71 14.99±2.58
P value (within groups) 0.030 0.001 0.118 0.774
FSI
Pre-test -0.78±0.76 -0.48±0.79 -0.52±0.87 -0.90±0.49
0.822Post-test -1.04±0.7696 -0.85±0.63 -0.80±0.95 -1.01±0.53
P value (within groups) 0.034 0.021 0.053 0.075
HSI
Pre-test 73.69±7.25 76.42±6.21 76.45±6.52 74.11±6.91
0.752Post-test 71.55±6.66 74.09±5.57 73.69±6.78 73.24±7.23
P value (within groups) 0.014 0.027 0.023 0.398
Abbreviations: RT, Resistance training; GC, Green coffee; P, placebo; ALT, Alanine aminotransferases; AST, Aspartate aminotransferases; GGT, Gamma glutamyl 
transferase; HIS, Hepatic steatosis index; FSI, Framingham steatosis index; FBG, Fasting blood glucose; BMI, Body mass index; HDL, High density lipoprotein; TG, 
Triglyceride; WC, Waist circumference; MAP, Mean arterial pressure; WHR, Waist-to-hip ratio.
* * P< 0.05
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and FBG levels as well as FSI and HSI. The GC dose used 
in the present study provided 250 mg of CGA per day. 
This amount of CGA may be achieved by daily intake of 
coffee that may include 0.5 to 1.0 g of CGA per day (26). 
However, in Iranian population, especially in the region 
of this study, the consumption of GC and other drinks 
containing CGA is not common, and therefore a daily 
dose of 500 mg of GC is appropriate (27). Furthermore, 
at baseline, both groups consumed approximately equal 
amounts of macronutrient composition such as fat, 
carbohydrates, and protein, and number of calories per 
day and had a similar dietary pattern.
The GC and RT treatments were not effective in 
reducing liver enzymes and hepatic steatosis biomarkers. 
The association between GC intake and hepatic steatosis 
biomarkers has not yet been studied. In the present study, 
insignificant changes in circulating liver enzymes were 
also observed in the experimental groups compared with 
placebo. However, the degree of steatosis was not measured 
in this study. 
In contrast to the present study, previous investigations 
revealed that increased coffee consumption was associated 
with lower liver enzymes and liver‐related mortality 
(28,29). In fact, the purpose of this study was not to 
examine NAFLD with focus on non-invasive indices 
of fatty liver (FSI and HSI), which have been shown to 
be highly correlated with ultrasonographic fatty liver 
(22,30,31). No improvements in noninvasive hepatic 
biomarkers were observed in the three studied groups 
throughout the present study since AST and ALT did 
not decrease significantly. As previously reported, of 
the parameters used to calculate these hepatic steatosis 
biomarkers, changes in BMI, waist circumference, TG, 
and HDL cholesterol were not significantly more marked 
in participants in experimental groups than in placebo 
groups in this study. 
It has been hypothesized that these interventions 
might modulate FSI in a different manner. The results 
of the present 8-week study conducted on obese women 
with hepatic disorders showed that multi-interventions 
might not be sufficient to improve hepatic disorders. It 
has recently been shown that a significant improvement 
in bright liver score is achieved following a 6-month 
Mediterranean diet intervention and exercise training 
(32); however, fatty liver changes were not significant at 
the first and third months of monitoring. 
It was found that decreases in FSI were not significant 
in experimental groups compared with placebo. There has 
yet been no published study directly assessing the effects 
of exercise training and supplement on FSI in adults. It 
can be speculated that exercise alone or along with GC 
is likely insufficient to improve FSI in all groups. The 
results of the present study confirmed the hypothesis that 
RT did not improve FSI in a superior manner compared 
to combined RT and GC in obese women. It seems that 
these non-significant decreases in FSI are dependent on 
body composition in obese women (33) because it has 
been demonstrated that the level of improvement in 
hepatic biomarkers of obese subjects after exercise training 
intervention is associated with the degree of weight loss. In 
addition, it has been previously shown that the beneficial 
effects of coffee on liver parameters might be manifested in 
patients with chronic liver diseases (28). 
However, it is possible that significant differences 
between the four subgroups would have emerged if 
treatments were of longer duration (34). These findings 
are not in line with a number of studies that provided 
evidence in support of CGA and GC extract as an 
effective compound in lowering fatty liver (35-38). 
Shahmohammadi et al (3) were the first to show that GC 
supplementation significantly improved the level of AST. 
Recently, Tajik et al have reported in a review article that 
CGA is able to exert pivotal roles on hepatic steatosis (39). 
The discrepancy in the effects of CGA in GC between the 
present study and others might be explained by different 
methods of CGA administration. Additionally, the dose 
and duration used in these trials might explain some of 
the variations in findings compared to the present study. 
Consistent with previous reports (40), the present trial did 
not support the hypothesis that the supplementation of 
GC will improve hepato-metabolic complications in obese 
individuals. Most studies have addressed hepatic steatosis 
regulation during low-to-moderate aerobic training, but 
other kinds of training such as resistance training may be 
different. 
Limitations of the Study
The present study had several potential limitations. 
First, the small size of the subjects could be considered 
as a limitation of the study. Second, given the ethical and 
practical considerations, it was not possible to conduct a 
repeated liver biopsy for histology analysis. Therefore, the 
hepatic fat content was not measured by the laboratory. 
Third, no ultrasonography was utilized to detect fatty 
liver, which was another limitation of the present study. 
In addition, the short duration of the study could be 
considered as the other limitation of this study. Further 
interventional studies on animals and humans are required 
to determine if GC is able to protect against fatty liver or 
not.
Conclusion
In summary, no significant decrease was found in hepatic 
steatosis in middle-aged obese women. Therefore, it 
is suggested that resistance exercises and other kinds 
of exercise training along with GC supplement might 
have the potential to improve hepatic steatosis indices 
in a longer duration. Additionally, higher GC dosage is 
suggested for future studies.
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